Atrial Fibrillation in Cancer Patients: Who is at Risk?
Rational Pharmacotherapy in Cardiology,
Journal Year:
2022,
Volume and Issue:
17(6), P. 900 - 907
Published: Jan. 11, 2022
Cancer
is
the
second
leading
cause
of
mortality
in
world,
only
to
cardiovascular
diseases.
Simultaneously
cancer
has
been
steadily
decreasing
due
development
new
chemotherapy
and
targeted
drugs
improvement
existing
treatment
protocols.
Improving
prognosis
patients
leads
an
unexpected
result
-
more
are
faced
with
side
effects
treatment.
Cardiotoxicity,
including
arrhythmia,
become
a
significant
factor
reduce
effectiveness
patient’s
Atrial
fibrillation
frequent
persistent
rhythm
disorder,
affecting
all
categories
patients,
especially
elderly.
An
association
between
these
two
conditions
can
be
expected,
considering
fact
that
old
age
prevalence
malignant
neoplasms
comorbid
pathology
predisposing
onset
AF
high.
Therefore,
may
additional
negatively
influencing
tactics
neoplasms.
A
comprehensive
search
was
conducted
using
keywords
“cancer”,
“atrial
fibrillation”
“cardiotoxicity”
PubMed,
Scopus
Cohrane
databases.
We
reviewed
publications
having
relationship
cancer.
The
literature
review
considered
61
on
classification,
mechanisms
development,
effect
anticancer
other
methods
this
group
patients.
Analyzed
articles
include
clinical
guidelines,
consensus
expert
opinions,
systematic
reviews,
meta-analyzes,
previously
published
reviews
literature.
problem
cardiotoxic
complications
diagnostics
evaluated
separately,
incl.
arrhythmias,
their
monitoring
direction
medicine
named
"Cardio-oncology"
comes
fore.
Interdisciplinary
interaction
will
allow
identify
manifestations
at
subclinical
stage
optimize
Language: Английский
Some groups of drugs which use is associated with development of drug-induced atrial fibrillation
Medical alphabet,
Journal Year:
2021,
Volume and Issue:
1(11), P. 20 - 28
Published: June 15, 2021
Recently,
more
and
attention
has
been
paid
to
the
problem
of
drug‑induced
(DI)
atrial
fibrillation
(AF).
It
is
known
that
development
DI
AF
can
be
associated
with
intake
cardiovascular
anticancer
drugs,
drugs
affect
central
nervous
system
or
respiratory
organs.
However,
there
are
other
provoke
AF,
which
practitioners
less
aware
of.
This
article
a
review
current
literature
on
groups
individual
not
included
in
above
groups.
Analysis
available
shown
incidence
reaches
6.9%
when
taking
zoledronic
acid
1.5%
alendronate,
although
data
from
different
authors
regarding
causal
relationship
between
bisphosphonate
therapy
ambiguous.
The
use
high
doses
glucocorticosteroids
(at
daily
dose
≥
7.5
mg
terms
prednisolone)
also
an
increased
risk
(OR
=
6.07;
95%
CI:
3.90–9.42).
Treatment
non‑steroidal
anti‑inflammatory
higher
developing
compared
those
who
do
it
–
rate
1.17
(95%
1.10–1.24)
for
nonselective
1.27
1.20–1.34)
cyclooxygenase‑2
inhibitors.
contains
description
clinical
cases
while
immunosuppressants
(azathioprine,
methotrexate
+
etanercept,
fingolimod,
cyclosporine),
genitourinary
(vardenafil,
sildenafil,
yohimbine
hydrochloride,
hexoprenaline),
local
anesthetics,
bupacaero
testosterone,
stanozolol,
testosterone
cypionate,
nandrolone
decanoate
extraboline)
nicotine‑containing
products
(nicotine‑containing
chewing
gum).
Language: Английский
Drug-Induced Atrial Fibrillation / Atrial Flutter
О. Д. Остроумова,
No information about this author
M. S. Chernyaeva,
No information about this author
А. И. Кочетков
No information about this author
et al.
Rational Pharmacotherapy in Cardiology,
Journal Year:
2022,
Volume and Issue:
17(6), P. 1 - 18
Published: Jan. 12, 2022
Drug-induced
atrial
fibrillation
/
flutter
(DIAF)
is
a
serious
and
potentially
life-threatening
complication
of
pharmacotherapy.
Purpose
the
work:
systematization
analysis
scientific
literature
data
on
drugs,
use
which
can
cause
development
DIAF,
as
well
epidemiology,
pathophysiological
mechanisms,
risk
factors,
clinical
picture,
diagnosis
differential
diagnosis,
treatment
prevention
DIAF.
Analysis
has
shown
that
many
groups
drugs
with
greater
frequency
while
taking
anticancer
for
cardiovascular,
bronchopulmonary
central
nervous
systems.
The
mechanisms
main
factors
DIAF
have
not
been
finally
established
are
known
only
certain
therefore,
this
section
requires
further
study.
symptoms
due
to
severity
tachycardia
their
influence
parameters
hemodynamics.
For
it
necessary
conduct
an
electrocardiogram
(ECG)
Holter
monitoring
ECG
echocardiography.
Differential
should
be
made
AF,
may
caused
by
other
causes,
rhythm
conduction
disturbances.
Successful
based
principle
rapid
recognition
immediate
discontinuation
(if
possible),
adverse
drug
reactions
(ADR).
choice
management
strategy:
heart
rate
control
or
control,
method
achievement
(medication
non-medication),
depends
specific
situation.
instruct
patients
about
possible
recommend
self-monitoring
pulse.
It
important
practitioners
wary
variety
ADR.
Language: Английский
Cardiotoxic Effects of Yew Tree and Pink Periwinkle Alkaloids
Safety and Risk of Pharmacotherapy,
Journal Year:
2021,
Volume and Issue:
9(4), P. 165 - 172
Published: Nov. 8, 2021
Antitumour
herbal
medicines
based
on
pink
periwinkle
and
yew
tree
alkaloids
are
included
in
combination
therapies
for
many
types
of
cancer.
The
use
these
classes
products
may
entail
cardiotoxic
effects
leading
to
life-threatening
conditions.
aim
the
study
was
analyse
scientific
literature
anticancer
drugs
(taxanes)
(vinca
alkaloids).
results
analysis
demonstrated
that
main
manifestations
taxane-induced
cardiotoxicity
were
bradycardia,
atrioventricular
block,
atrial
ventricular
arrhythmias.
Concomitant
taxanes
anthracycline
antibiotics
exacerbated
both
drug
classes.
vinca
associated
with
haematological
toxicity
form
neutropenia,
while
effect
rarely
observed
during
monotherapy.
Raising
awareness
among
oncologists,
cardiologists,
other
specialists
involved
management
cancer
patients
about
potential
cardiac
complications
antitumour
therapy
contributes
early
detection
adverse
reactions
allows
individual
correction
treatment
regimens,
especially
predisposition
cardiovascular
disease.
Language: Английский